BTIG lowered the firm’s price target on Blue Bird (BLBD) to $45 from $55 and keeps a Buy rating on the shares. The company’s higher than ...

BTIG analyst Gregory Lewis (JO:LEWJ) revised the price target for Blue Bird Corp (NASDAQ:BLBD) shares to $45.00, down from the previous target of $55.00, while reaffirming a Buy rating on the stock.

BTIG analyst Gregory Lewis maintained a Buy rating on Blue Bird (BLBD – Research Report) today and set a price target of $45.00. The company’s ...

BTIG Research lowered shares of IQVIA (NYSE:IQV – Free Report) from a buy rating to a neutral rating in a research report report published on Monday morning, Marketbeat.com reports. Several other ...

BTIG analysts stood firm on their positive stance towards GeneDx (NASDAQ:WGS), reiterating a Buy rating and a $95.00 price target for the company's stock. With analyst targets ranging from $70 to $118 ...

This partnership addresses the growing demand among institutional traders for advanced, centralised technology that enables ...

While value offerings are helping improve sales, some franchisees have yet to fully recover their visits and sales comps as ...

Treace provides technology that facilitates Lapiplasty bunion surgery and related midfoot deformities. The company recently ...

For more information about the event, visit InMode's investor relations site here.